Mursla: Funding, Investors & Team (Oct 2026)
Mursla is a breakthrough exosome characterisation company based on a novel proprietary technology platform, ExoPheno™, which detects the multi-omics cargo of tissue-specific exosomes in blood for various biomedical applications. Exosomes (also known as Extracellular Vesicles) have been shown to reflect the state of their cellular sources, transporting specific ‘-omics’ information (DNA, RNA, proteins, lipids and metabolites) either locally or to distant sites via the circulatory system, including blood.
Mursla has raised $100k across 1 funding round on record, the most recent a Grant of $100k announced in Mar 2022.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mursla Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Mursla Funding Rounds
Mursla Founders and Leadership Team
Contact details for the Mursla team: 1 of 1 has an email address on file.
Start 14-day free trial →Mursla Funding Compared to Other Biotechnology Startups
Mursla's latest round of $100k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mursla in Biotechnology and Cambridge
Companies Similar to Mursla
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Mursla Funding FAQs
What does Mursla do?
Mursla is a breakthrough exosome characterisation company based on a novel proprietary technology platform, ExoPheno™, which detects the multi-omics cargo of tissue-specific exosomes in blood for various biomedical applications. Exosomes (also known as Extracellular Vesicles) have been shown to reflect the state of their cellular sources, transporting specific ‘-omics’ information (DNA, RNA, proteins, lipids and metabolites) either locally or to distant sites via the circulatory system, including blood.
How much funding has Mursla raised?
Mursla has raised $100k across 1 round on record. The most recent is a Grant of $100k announced in Mar 2022.
When did Mursla last raise funding?
Mursla's most recent funding round on record is a Grant of $100k, announced in Mar 2022.
Who founded Mursla?
FundedIQ lists Pierre Arsene (Founder and CEO) at Mursla.
Where is Mursla headquartered?
Mursla is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does Mursla have?
Mursla is in the 1-10 employee band.
How does Mursla's funding compare to other Biotechnology startups?
Mursla's latest round of $100k is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Mursla Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mursla is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.